You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Lung cancer

Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer

  • Technology appraisal guidance
  • Reference number: TA1071
  • Published:  19 June 2025
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Final draft guidance
  2. Invitation to participate
  3. Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

History

Documents created during the development process.

Final draft guidance

  • Final draft guidance

  • Final draft guidance (PDF 131 KB)

    Published:
    15 May 2025
  • Committee papers (PDF 8.06 MB)

    Published:
    15 May 2025
  • Equality impact assessment (downloadable version) (PDF 110 KB)

    Published:
    15 May 2025

Invitation to participate

  • Final scope (PDF 188 KB)

    Published:
    02 October 2024
  • Final stakeholder list (PDF 172 KB)

    Published:
    02 October 2024
  • NICE's response to comments on the draft scope and provisional stakeholder list (PDF 270 KB)

    Published:
    02 October 2024
  • Equality impact assessment (scoping) (PDF 127 KB)

    Published:
    02 October 2024

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

  • Draft matrix post referral (PDF 173 KB)

    Published:
    21 August 2024
  • Draft scope post referral (PDF 196 KB)

    Published:
    21 August 2024
Back to top